Skip to main content

Table 1 Patient characteristics and CTC-HER status

From: The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients

  Total CTC-HER2-positive p-value
Total, n (%) 107 37 (35)  
Age at primary diagnosis, years; median (range) 49 (33–81) 49 (35–77) 0.594
Age at enrollment, years; median (range) 57 (33–81) 58 (40–77) 0.517
ER status, n (%)    0.253
 Negative 78 30 (38)  
 Positive 29 7 (24)  
PR status, n (%)    0.673
 Negative 68 25 (37)  
 Positive 39 12 (31)  
Number of metastatic sites, n (%)    0.799
 One site 21 8 (38)  
 Multiple sites 86 29 (34)  
Site of metastasis, n (%)    0.626
 Bone 19 5 (26)  
 Visceral 22 7 (32)  
 Both 66 25 (38)  
Line of therapy, n (%)a    0.268
 First 51 18 (35)  
 Second 22 10 (45)  
 Further 33 8 (24)  
  1. ER estrogen receptor, PR progesterone receptor
  2. aLine of therapy unknown for one patient